Result for
Topic: Vaccines and Immunity
May 5, 2021
Evaluation of Potential COVID-19 Recurrence in Patients with Late Repeat Positive SARS-CoV-2 Testing
Among 23,176 patients with a positive SARS-CoV-2 in Utah between March and July 2020, 4 of 1,301 patients with at least one additional PCR test ≥60 days after the initial positive test were identified to have probable reinfection and 6 additional patients had possible reinfection. Reinfection was assessed using combined clinical and RT-PCR cycle threshold…
May 4, 2021
Varicella-Zoster Virus Reactivation after SARS-Cov2 BNT162b2 MRNA Vaccination: Report of Five Cases
A series of 5 cases of herpes zoster reactivation were observed among a healthcare worker cohort in Spain that received at least the first dose of the Pfizer-BioNTech vaccine (n=3,707) over a period of four weeks. Three patients presented with herpes zoster after the first dose, while two presented after the second dose. All patients…
SARS -CoV-2 T-Cell Immunity to Variants of Concern Following Vaccination
[Pre-print, not peer-reviewed] A study using two standardized, functional assays to measure memory T cell immunity to SARS-CoV-2 found that individuals vaccinated with the COVID-19 mRNA vaccines (n=29) mounted a more robust T cell response than convalescent patients (n=19) or healthy controls with no prior infection (n=25). The assay was based upon the “Quantiferon Gold”…
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Incidence of SARS-CoV-2 infection was 95% lower among persons with prior SARS-CoV-2 infection, indicated by seropositivity, in a cohort study in Qatar. In the study, 129 of 43,044 seropositive persons (0.3%) followed for a median of 16 weeks had at least one positive PCR test supported by evidence of reinfection at least 14 days after…
May 3, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
A case series of 12 patients in the US who experienced cerebral venous sinus thrombosis (CVST) with thrombocytopenia following the Johnson & Johnson/Janssen vaccine found that all patients were women under the age of 60 who began experiencing symptoms that required hospitalization between 6 and 15 days after vaccination. Seven patients had at least 1…
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
A case series of 12 patients in the US who experienced cerebral venous sinus thrombosis (CVST) with thrombocytopenia following the Johnson & Johnson/Janssen vaccine found that all patients were women under the age of 60 who began experiencing symptoms that required hospitalization between 6 and 15 days after vaccination. Seven patients had at least 1…
Prior SARS-CoV-2 Infection Rescues B and T Cell Responses to Variants after First Vaccine Dose
An analysis of B and T cell responses in healthcare workers who received one dose of the Pfizer-BioNTech vaccine showed that individuals with prior infection had enhanced T cell immunity and neutralizing antibodies effective against the B.1.1.7 and B.1.351 variants, while those without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations…
SARS-CoV-2 Antibodies Remain Detectable 12 Months after Infection and Antibody Magnitude Is Associated with Age and COVID-19 Severity
[Pre-print, not peer-reviewed] An analysis of longitudinal serum samples collected from U.S. active duty service members, dependents, and military retirees with PCR-confirmed SARS-CoV-2 infection between March 2020 and March 2021 found 100% seropositivity among inpatients followed for six months (58/58) to one year (8/8). Seroreversion was observed in 5% (9/192) of outpatients six to ten…
Weak Immunogenicity after a Single Dose of SARS-CoV-2 MRNA Vaccine in Treated Cancer Patients
Nearly half of patients with cancer (CP) at a hospital in France showed no anti-spike antibody response four weeks after one dose of the Pfizer-BioNTech vaccine, while 100% of healthcare workers (HCW) vaccinated at the same time (between February 17 and March 18, 2021) had developed anti-spike antibodies (seroconversion). Anti-S IgG titers were also significantly…
Real-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19
[Pre-print, not peer-reviewed] The Johnson & Johnson/Janssen vaccine showed a real-world effectiveness of 76.7% in preventing SARS-CoV-2 infection at least two weeks after vaccination among patients in the Mayo Clinic Health system, according to an analysis comparing the infection rate among 2,195 individuals who received the vaccine to that among 21,950 unvaccinated, propensity-matched individuals between…
Previous page Next page